|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Ibutamoren
Description of
Ibutamoren:
Ibutamoren, also known as MK-677 (L-163,191), is a drug which acts as a potent,
orally active growth hormone secretagogue, mimicking the GH
stimulating action of the endogenous hormone ghrelin. It has been
demonstrated to increase the release of, and produces sustained
increases in plasma levels of several hormones including growth hormone
and IGF-1, but without affecting cortisol levels. It is currently
under development as a potential treatment for reduced levels of these
hormones, such as in growth hormone deficient children or elderly
adults, and human studies have shown it to increase both muscle mass and
bone mineral density, making it a promising therapy for the
treatment of frailty in the elderly. It also alters metabolism of body
fat and so may have application in the treatment of obesity. See
wikipedia.com.
Current developer:
Merck
|
MedKoo Code#:
201684
|
|
Name:
Ibutamoren
|
|
CAS#:
159634-47-6
Synonym: Ibutamoren;
L 163191; MK-0677; MK-677.
IUPAC/Chemical name:
2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-(phenylmethoxy)propan-2-yl]propanamide
|
|
Chemical structure: |
Theoretical analysis
|
|
|
MedKoo Code#: 201684
Name: Ibutamoren
CAS#: 159634-47-6
Chemical Formula: C27H36N4O5S
Exact Mass: 528.24064
Molecular Weight: 528.66
Elemental Analysis: C, 61.34; H, 6.86; N,
10.60; O, 15.13; S, 6.07
|
|
Availability and price:
Ibutamoren is available through custom synthesis.
To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
1: Bennett KA, Langmead CJ, Wise A, Milligan G.
Growth hormone secretagogues and growth hormone releasing peptides act
as orthosteric super-agonists but not allosteric regulators for
activation of the G protein Galpha(o1) by the Ghrelin receptor. Mol
Pharmacol. 2009 Oct;76(4):802-11. Epub 2009 Jul 22. PubMed PMID:
19625579; PubMed Central PMCID: PMC2769045.
2: Hakim RM, Ikizler TA. Anabolic interventions in ESRD: light at the
end of the tunnel? Am J Kidney Dis. 2009 Aug;54(2):201-4. Epub 2009 Jun
25. PubMed PMID: 19556045.
3: Webster J. Rejuvenation in older adults receiving oral ghrelin. Ann
Intern Med. 2009 May 5;150(9):654-5; author reply 655. PubMed PMID:
19414853.
4: Gaugg M. Rejuvenation in older adults receiving oral ghrelin. Ann
Intern Med. 2009 May 5;150(9):654; author reply 655. PubMed PMID:
19414852.
5: Rafael H. Rejuvenation in older adults receiving oral ghrelin. Ann
Intern Med. 2009 May 5;150(9):653-4; author reply 655. PubMed PMID:
19414850.
6: Hanauer SB. Sarcopenia and the elusive fountain of youth. Nat Clin
Pract Gastroenterol Hepatol. 2009 Jan;6(1):1. PubMed PMID: 19127276.
7: Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML; MK-677
Protocol 30 Study Group. Growth hormone secretagogue MK-677: no clinical
effect on AD progression in a randomized trial. Neurology. 2008 Nov
18;71(21):1702-8. PubMed PMID: 19015485.
8: Blackman MR. Use of growth hormone secretagogues to prevent or treat
the effects of aging: not yet ready for prime time. Ann Intern Med. 2008
Nov 4;149(9):677-9. PubMed PMID: 18981489.
9: Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL,
Heymsfield SB, Bach MA, Vance ML, Thorner MO. Effects of an oral ghrelin
mimetic on body composition and clinical outcomes in healthy older
adults: a randomized trial. Ann Intern Med. 2008 Nov 4;149(9):601-11.
PubMed PMID: 18981485; PubMed Central PMCID: PMC2757071.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
